Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eflornithine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ODC1 known ✓ | P11926 | 2/20 | 0.92 |
| ▸ | BLM | P54132 | 3/20 | 0.96 |
| ▸ | LMNA | P02545 | 3/20 | 0.96 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.96 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | ARG2 | P78540 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Eflornithine SCHEMBL3238104 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL559145 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL4809264 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL5051665 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL1397750 | 1.00 | BLM (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| D-Eflornithine SCHEMBL7208883 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL6779168 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL6779172 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine SCHEMBL3244711 | 0.98 | ODC1 (0.96) | BLMLMNAKDM4EMAPTRAB9A | |
| Eflornithine, (S)- SCHEMBL1322403 | 0.98 | BLM (1.00) | BLMLMNAKDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8577 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137642-A1 | METHODS OF TREATING PATIENTS HAVING TYPE 1 DIABETES WITH EFLORNITHINE | CANCER PREVENTION PHARMACEUTICALS, INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12605349-B2 | Methods of treating grade 3 astrocytoma | Orbus Therapeutics, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| US-20260060950-A1 | METHODS OF TREATING GRADE 3 ASTROCYTOMA | ORBUS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| WO-2025050100-A1 | COMPOSITIONS AND METHODS FOR TREATING HAIR AND SKIN CONDITIONS RELATED TO FOLLICULOPILOSEBACEOUS UNITS | OLSEN ELISE A (US) | 2025-03-06 | — | — | WO | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| WO-2024220593-A1 | COMPOSITIONS AND METHODS FOR PREVENTION OF CHEMOTHERAPY- OR RADIATION-RELATED HAIR LOSS | OLSEN ELISE A (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-6764493-B1 | Tissue removal using biocompatible materials | PEARL TECHNOLOGY HOLDINGS, LLC | 2004-07-20 | — | — | US | claimed |
| US-6730809-B2 | FORMED VIA CHEMICAL REDUCTION AND HYDROLYSIS WITH MINIMAL USE OF HALOGENATED SOLVENTS; COMPRISES USE OF INTERMEDIATES SUCH AS ETHYL 2-BENZYLIDENEAMINO-2-DIFLUOROMETHYL-4-CYANOBUTANOATE | WOMEN FIRST HEALTHCARE, INC. | 2004-05-04 | — | — | US | claimed |
| EP-1311266-A2 | COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN | SuperGen, Inc. (US) | 2003-05-21 | — | — | EP | claimed |
| US-20030083384-A1 | Processes for the production of alpha-difluoromethyl ornithine (DFMO) | BRISTOL-MYERS SQUIBB COMPANY TO WOMEN FIRST HEALTHCARE, INC. | 2003-05-01 | — | — | US | claimed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | claimed |
| EP-0692963-B1 | USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS | VSL PHARMA LTD (IE) | 2002-06-26 | — | — | EP | claimed |
| WO-2002038125-A2 | TISSUE REMOVAL USING BIOCOMPATIBLE MATERIALS | PEARL TECHNOLOGY HOLDINGS, LLC (US) | 2002-05-16 | — | — | WO | claimed |
| WO-2002000168-A2 | COMBINATION HIV THERAPY INCLUDING CAMPTOTHECIN | SUPERGEN, INC. (US) | 2002-01-03 | — | — | WO | claimed |
| EP-0692963-A1 | USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS | Mendes S.R.L. (IT) | 1996-01-24 | — | — | EP | claimed |
| WO-1994020082-A1 | USE OF TERBINAFINE FOR THE THERAPEUTIC TREATMENT OF PNEUMOCYSTOSIS | MENDES S.R.L. (IT) | 1994-09-15 | — | — | WO | claimed |